statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has received an average rating of "Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $41.50 Average PT from Analysts

Even if it's not a huge purchase, we think it was good to see that David Happel, the CEO, President & Director of...

Sagimet Biosciences CEO, President & Director Acquires 553% More Stock

Sagimet Biosciences (NASDAQ:SGMT  Free Report) had its price objective cut by The Goldman Sachs Group from $37.00 to $27.00 in a report issued on Tuesday, Benzinga reports. They currently have...

Sagimet Biosciences (NASDAQ:SGMT) PT Lowered to $27.00 at The Goldman Sachs Group

Leerink Partnrs restated their outperform rating on shares of Sagimet Biosciences (NASDAQ:SGMT  Free Report) in a research report released on Monday, Zacks.com reports. Leerink Partnrs also...

Sagimet Biosciences (NASDAQ:SGMT) Rating Reiterated by Leerink Partnrs

Leerink Partnrs reiterated their outperform rating on shares of Sagimet Biosciences (NASDAQ:SGMT  Free Report) in a research report report published on Monday morning, Zacks.com reports...

Sagimet Biosciences (NASDAQ:SGMT) Given "Outperform" Rating at Leerink Partnrs

Comparing SGMT's Performance Against Analyst Estimates and Future ProspectsRelated Stocks: SGMT...

Sagimet Biosciences Inc (SGMT) Reports Full Year 2023 Financial Results: A Close Look

SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Equities research analysts at SVB Leerink assumed coverage on shares of Sagimet Biosciences (NASDAQ:SGMT  Get Free Report) in a report released on Monday, MarketBeat.com reports. The firm set...

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at SVB Leerink

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sagimet Biosciences expects cash to fund operations for at least next 12 months

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Volume	308,933.00
52-Wk High	$20.71
52-Wk Low	$2.13

SGMT Sagimet Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals